Increasing the expression of the CYP39A1 protein has the potential to suppress 24S-hydroxycholesterol aggregation in the brain and act as a therapeutic target for neurodegenerative diseases involving abnormal amyloid-β accumulation such as Alzheimer’s disease (Matsuoka et al., 2020). This evidence concerns the gene CYP39A1 and neurodegenerative disease.